靶向STING的PET示踪剂用于早期评估结直肠癌化疗后的肿瘤免疫原性
研究用靶向干扰素基因刺激因子(STING)的PET示踪剂[18F]FBTA,在结直肠癌小鼠中监测奥沙利铂或顺铂化疗后肿瘤免疫原性的早期变化。结果显示奥沙利铂组肿瘤摄取为3.09 ± 0.25%ID/g,顺铂组为4.01 ± 0.18%ID/g,顺铂组更高,且PET摄取与STING免疫组化评分强相关。作者认为该STING靶向策略可能有助于选择化疗方案(包括药物和剂量),以改善化疗后联合免疫治疗的临床决策。
要点
- 结直肠癌小鼠化疗早期,[18F]FBTA PET肿瘤摄取在顺铂组(4.01 ± 0.18%ID/g)高于奥沙利铂组(3.09 ± 0.25%ID/g)。
- PET衍生的肿瘤摄取值与STING免疫组化评分强相关。
- 顺铂中剂量组肿瘤摄取升高,且招募的树突状细胞和巨噬细胞多于低剂量组。
核心结论
- STING靶向示踪剂[18F]FBTA可监测结直肠癌小鼠化疗后肿瘤免疫原性的早期变化。
- 作者认为STING靶向策略可能有助于选择适当的化疗方案,包括化疗药物和剂量,从而进一步改善结直肠癌化疗后联合免疫治疗的临床决策。
研究设计与样本
- 研究用甲苯磺酸酯前体经18F标记制备STING靶向探针[18F]FBTA。
- 使用奥沙利铂或顺铂治疗的结直肠癌小鼠进行[18F]FBTA PET成像和生物分布研究。
- 结直肠癌小鼠还接受低剂量顺铂(CDDP-LD:1 mg/kg)或中剂量顺铂(CDDP-MD:2.5 mg/kg)治疗,并进行PET成像和生物分布研究。
- 用流式细胞术和免疫组化验证不同化疗药物及不同剂量顺铂对肿瘤先天免疫的影响。
主要发现
- 结直肠癌小鼠PET成像显示,奥沙利铂组化疗早期肿瘤摄取为3.09 ± 0.25%ID/g,顺铂组为4.01 ± 0.18%ID/g,顺铂组尤为明显。
- PET衍生的肿瘤摄取值与STING免疫组化评分强相关。
- 流式细胞术显示两种药物均导致肿瘤内树突状细胞和巨噬细胞浸润。
- 与奥沙利铂相比,顺铂治疗在结直肠癌肿瘤中招募更多树突状细胞和巨噬细胞。
- 低剂量和中剂量顺铂治疗均升高结直肠癌肿瘤摄取,中剂量顺铂组尤为明显;免疫组化和流式细胞术证实中剂量顺铂治疗比低剂量顺铂治疗招募更多树突状细胞和巨噬细胞。
关键数值与推荐
- 奥沙利铂组肿瘤摄取为3.09 ± 0.25%ID/g,顺铂组为4.01 ± 0.18%ID/g。
- 低剂量顺铂为1 mg/kg,中剂量顺铂为2.5 mg/kg。
- PET衍生的肿瘤摄取值与STING免疫组化评分强相关。
- 中剂量顺铂治疗比低剂量顺铂治疗招募更多树突状细胞和巨噬细胞。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To optimize chemotherapy regimens and improve the effectiveness of chemotherapy combined with immunotherapy, a PET tracer specifically targeting the stimulator of interferon genes (STING), denoted as [18F]FBTA was used to monitor the early changes in tumor immunogenicity after chemotherapy in colorectal cancer (CRC) mice. METHODS: The toluene sulfonate precursor was labeled with 18F to produce the STING targeted probe-[18F]FBTA. [18F]FBTA-PET imaging and biodistribution were performed using CRC mice treated with oxaliplatin (OXA) or cisplatin (CDDP). CRC mice were also treated with low (CDDP-LD: 1 mg/kg) or medium (CDDP-MD: 2.5 mg/kg) doses of CDDP, and subjected to PET imaging and biodistribution. The effects of different chemotherapeutic agents and different doses of CDDP on tumor innate immunity were verified by flow cytometry and immunohistochemistry. RESULTS: PET imaging of CRC mice exhibited notably enhanced tumor uptake in the early phase of chemotherapy with treatment with OXA (3.09 ± 0.25%ID/g) and CDDP (4.01 ± 0.18%ID/g), especially in the CDDP group. The PET-derived tumor uptake values have strong correlations with STING immunohistochemical score. Flow cytometry showed both agents led to DCs and macrophages infiltration in tumors. Compared with OXA, CDDP treatment recruits more DCs and macrophages in CRC tumors. Both CDDP-LD and CDDP-MD treatment elevated uptake in CRC tumors, especially in CDDP-MD group. Immunohistochemistry and flow cytometry confirmed CDDP-MD treatment recruits more DCs and macrophages than CDDP-LD treatment. CONCLUSION: Overall, the STING-targeted tracer-[18F]FBTA was demonstrated to monitor early changes in tumor immunogenicity in CRC mice after chemotherapy. Besides, the STING-targeted strategy may help to select the appropriate chemotherapy regimen, including chemotherapeutic agents and doses, which further improve clinical decision making for combination immunotherapy after chemotherapy for CRC.
引用
- Xu D, Lu X, Yang F, et al. STING-targeted PET tracer for early assessment of tumor immunogenicity in colorectal cancer after chemotherapy. Eur J Nucl Med Mol Imaging. 2023. PMID: 37924341. doi:10.1007/s00259-023-06485-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。